SCHEMBL13969348

SCHEMBL13969348

CC1N(C)c2cccc3c2N1c1ccccc1O3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ P2RX4 Q99571 12/20 0.39
▸ MAPT P10636 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.33
▸ P2RX1 P51575 1/20 0.33
▸ GPR3 P46089 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HBB P68871 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13951742 0.83 ALDH1A1 (0.40) KDM4EALDH1A1GAAHPGDALOX12
SCHEMBL13946287 0.71 KDM4E (0.41) KDM4EALDH1A1GAAHPGDALOX12
SCHEMBL47007 0.68 KDM4E (0.55) KDM4EALDH1A1GAAHPGDP2RX4
SCHEMBL31067286 0.68 KDM4E (0.55) KDM4EALDH1A1GAAHPGDP2RX4
SCHEMBL23656228 0.68 KDM4E (0.41) KDM4EALDH1A1GAAHPGDALOX12
SCHEMBL30353863 0.68 GAA (0.62) KDM4EALDH1A1GAAHPGDALOX12
SCHEMBL1049325 0.68 GAA (0.62) KDM4EALDH1A1GAAHPGDALOX12
SCHEMBL16420322 0.67 KDM4E (0.47) KDM4EALDH1A1GAAHPGDALOX12
SCHEMBL14244249 0.66 P2RX4 (0.47) P2RX4MAPTSMN1; SMN2NPSR1P2RX1
SCHEMBL30547086 0.66 P2RX4 (0.47) P2RX4MAPTSMN1; SMN2NPSR1P2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410280-B2 Process for preparing transition metal-carbene complexes BASF SE (DE) 2013-04-02 — — US disclosed
US-20090018330-A1 PROCESS FOR PREPARING TRANSITION METAL-CARBENE COMPLEXES BASF SE (DE) 2009-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018330-A1 PROCESS FOR PREPARING TRANSITION METAL-CARBENE COMPLEXES AP1M1, C1S, GPS1 KDM4E 4586/4885ALDH1A1 2893/4885GAA 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback